GlaxoSmithKline’s rheumatoid arthritis prospect misses phase 2 endpoint

GlaxoSmithKline has missed the primary endpoint in a phase 2 trial of rheumatoid arthritis prospect GSK3196165. The highest dose of the anti-GM-CSF antibody failed to beat the placebo on a disease activity score, but GSK plans to forge ahead with more clinical trials nonetheless.